TCR2 announced the appointment of experienced biotech executive Rosemary Harrison, Ph.D., as Chief Business and Strategy Officer where she will be responsible for supporting a range of activities including commercial strategy, operational planning, corporate partnerships and long-term growth opportunities.
TCR2 Therapeutics Inc.
Equities
TCRR
US87808K1060
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+50.01% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |